Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 12/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.54 |
| ▸ | DCLK1 | O15075 | 9/20 | 0.54 |
| ▸ | BRD4 | O60885 | 4/20 | 0.46 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.46 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10098691 | 0.81 | MAPK7 (0.56) | MAPK7LRRK2DCLK1BRD4BRDT | |
| SCHEMBL16065715 | 0.80 | TNK2 (0.40) | ALDH1A1 | |
| SCHEMBL23144757 | 0.77 | LRRK2 (0.58) | MAPK7LRRK2DCLK1BRD4BRDT | |
| SCHEMBL20628385 | 0.76 | DCLK1 (0.75) | MAPK7LRRK2DCLK1PIK3CDAURKA | |
| SCHEMBL25357908 | 0.75 | DCLK1 (0.52) | MAPK7LRRK2DCLK1BRD4BRDT | |
| SCHEMBL30526068 | 0.75 | DCLK1 (0.52) | MAPK7LRRK2DCLK1BRD4BRDT | |
| SCHEMBL23144758 | 0.75 | LRRK2 (0.61) | MAPK7LRRK2DCLK1BRD4BRDT | |
| SCHEMBL20628513 | 0.75 | LRRK2 (0.57) | MAPK7LRRK2DCLK1BRD4BRDT | |
| SCHEMBL21938543 | 0.74 | PIK3CD (0.76) | MAPK7LRRK2DCLK1BRD4BRDT | |
| SCHEMBL20628497 | 0.73 | PIK3CD (0.63) | MAPK7LRRK2DCLK1BRD4BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034132-B1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | DANA FARBER CANCER INST INC (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12551563-B2 | ERK5 degraders as therapeutics in cancer and inflammatory diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20220378919-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-01 | — | — | US | disclosed |
| EP-4034132-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2021061894-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170283422-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283422-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9676792-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676792-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-01-28 | — | — | US | disclosed |
| WO-2014145909-A2 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | MAPK7 292/4885LRRK2 324/4885DCLK1 483/4885 |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | MAPK7 292/4885LRRK2 324/4885DCLK1 483/4885 |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | MAPK7 292/4885LRRK2 324/4885DCLK1 483/4885 |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | MAPK7 292/4885LRRK2 324/4885DCLK1 483/4885 |
| US-20170283422-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | MAPK7 292/4885LRRK2 324/4885DCLK1 483/4885 |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | MAPK7 292/4885LRRK2 324/4885DCLK1 483/4885 |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | MAPK7 292/4885LRRK2 324/4885DCLK1 483/4885 |
| US-12551563-B2 | ERK5 degraders as therapeutics in cancer and inflammatory diseases | OXSR1, MAPK1, NGFR | MAPK7 30/4885LRRK2 340/4885DCLK1 2710/4885 |
| US-20220378919-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | MAPKAPK5, DUSP5, MAP3K5 | MAPK7 60/4885LRRK2 427/4885DCLK1 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.